HomeExamplesMCP & ModelsResearchDocumentationLoginBook a demo
HomeExamplesMCP & ModelsResearchDocumentationLoginBook a demo
← Back to Research

Investment Assessment

DT120: off-patent LSD, reworked into a $4.4B psychiatry bet

Lukas KidzinskiLukas KidzinskiJuly 1, 2026
PsychiatryCNSNeurosciencePsychedelicsSmall molecule

Investment assessment of DT120 / MM120 (Definium Therapeutics, formerly MindMed; NASDAQ: DFTX). As of July 1, 2026. Informational only, not investment advice.

Definium is turning a molecule the patent office released in 1965 into a psychiatry franchise the market values at $4.4B. DT120 is a pharmaceutical form of lysergide, the compound better known as LSD, given as a single supervised dose. The clinical data is strong, the composition-of-matter patent expired roughly 60 years ago, and whether the $4.4B holds turns almost entirely on how one regulatory question resolves.

−5.0 ptsGAD HAM-A vs placebo from one 100µg dose (95% CI −9.6 to −0.4)
−13.3 vs −5.2MDD MADRS vs placebo, Phase 3 Emerge (p < 0.0001)
$2.67–5.24BOur rNPV, base to bull, against a $4.4B market cap
39% vs ~65%Modeled program odds vs the odds the market prices in

One dose moved the endpoints

In the GAD Phase 2b (MMED008, JAMA 2025), a single 100µg dose lowered HAM-A anxiety by 5.0 points against placebo (95% CI −9.6 to −0.4), with 65% response at week 12. Standard-of-care SSRIs take weeks to act and are dosed daily and indefinitely. The MDD Phase 3 (Emerge) then read out positive, MADRS −13.3 versus −5.2 on placebo (p < 0.0001), advancing a second major indication straight past Phase 2.

The mechanism is what makes the single-dose durability plausible. One dose engages the 5-HT2A receptor and a BDNF/TrkB plasticity cascade that regrows cortical synapses, rather than topping up serotonin at the synapse the way a daily pill does.

A single supervised dose of DT120 activates the 5-HT2A receptor, releases BDNF, engages TrkB and an mTOR-driven plasticity cascade, and regrows cortical synapses for months-durable relief, versus daily SSRIs that only top up serotonin at the synapse.
Figure 1. One supervised dose engages a 5-HT2A → BDNF/TrkB plasticity cascade that regrows lost circuitry, producing relief that lasts months. Daily SSRIs top up serotonin at the synapse without rebuilding the circuit.

The value sits outside the molecule

Lysergide lost composition-of-matter protection around 1965. Anyone can make the compound. The $4.4B therefore rests on three things that are not the molecule: the defined-dose oral formulation, the data and regulatory exclusivity that run to roughly 2041, and the clinical package that no generic maker holds. A Breakthrough Therapy Designation in GAD (March 2024) and a UK ILAP designation add regulatory standing that a raw off-patent chemical cannot.

This inverts the usual biotech question. The bet is not whether a patent holds. It is whether a first-mover clinical and regulatory position on an old molecule is durable enough to earn a specialty-CNS return before fast-followers arrive.

Preview of the DT120 presentation Full deck

Full presentation

See the full DT120 deck

We’ll email you the link to the full slide deck.

Blinding decides the approval

Psychedelic trials carry a problem that ordinary CNS trials do not. A 100µg dose of LSD produces unmistakable acute effects, so patients and often raters can tell drug from placebo. The formal blind stays intact while breaking in practice, which is called functional unblinding, and it lets expectancy inflate subjective scores like HAM-A and MADRS.

The precedent is recent and specific. In 2024 the FDA issued a Complete Response Letter to Lykos on MDMA-assisted therapy for PTSD. Both Phase 3s were statistically positive, roughly 90% of participants correctly guessed their arm, and the agency concluded it could not trust the effect size. A positive psychedelic Phase 3 can therefore still be rejected on blinding grounds.

DT120's program is built to blunt this. Panorama uses a 50µg dose as its control rather than inert placebo, so control subjects also feel an effect and the experiential gap narrows. The trials also report how accurately patients and raters guessed assignment, and guessing near chance is direct evidence the blind held. Months-long durability from a single dose is harder to explain as pure expectancy. If those blinding statistics read clean, the FDA can trust the HAM-A and MADRS effects. If they resemble the MDMA data, the strong numbers may not be enough.

The model and the price

Our probability-of-success model scores each registrational pivotal directly, without the entity-history features that inflate single-asset sponsors. The two GAD pivotals land at 27% (Panorama) and 35% (Voyage), MDD at 44% (Emerge), and the revenue-weighted program at 39%. The $4.4B market cap implies about 65%.

Approval probability by pivotal from Gosset's leak-free model: Panorama GAD 27%, Voyage GAD 35%, Emerge MDD 44%, blended program 39%, against a market-implied 65%.
Figure 2. The leak-free model prices GAD conservatively and MDD above it, for a blended 39%. That sits well below the ~65% the current cap implies.

The valuation follows from there. Base rNPV is $2.67B and bull is $5.24B, built as risk-adjusted peak revenue times a 2.5 NPV-of-stream multiple (base risk-adjusted peak $1.07B, bull $2.10B). The bull case reaches $5.24B, above the $4.4B cap, when the pivotals read clean and peak penetration reaches 15% in GAD and 10% in MDD. The base case sits below the market.

Valuation football field on a log scale: Gosset rNPV spans $2.67B base to $5.24B bull, risk-adjusted peak revenue $1.07B to $2.10B, comparable transactions up to $2.0B, against a $4.4B market cap line. The bull rNPV clears the cap; the base sits below it.
Figure 3. The bull rNPV clears the $4.4B cap; the base sits under it. The gap is a view on the probability of success and on penetration, and the pivotals adjudicate it.

The catalysts

Three Phase 3 readouts land in 2026, and each moves the odds the whole valuation turns on:

  • Voyage and Panorama GAD toplines. A positive read with blinding statistics near chance is the single largest re-rating, and it is what separates DT120 from the MDMA CRL.
  • Emerge MDD confirmation. The positive topline is in hand; the full dataset, durability, and blinding integrity carry it into the label.
  • FDA feedback on the 50µg blinding-control design. Agency acceptance of the control architecture converts the efficacy into an approvable package.

The caveats

  • Blinding, not efficacy, is the gating risk. The effect sizes are strong on paper. The MDMA CRL shows that the agency can still reject a positive psychedelic trial it believes was unblinded.
  • Throughput caps the commercial ramp. An 8–12 hour supervised session limits real capacity. Spravato reached only about 2% cumulative penetration in five years at J&J scale, which is the reference for the base-case penetration.
  • The molecule is free. Off-patent status means the moat is formulation, data exclusivity, and first-mover position, not the compound. Fast-followers on the same target are a medium-term threat.
  • Schedule I. DEA rescheduling is procedurally independent of FDA approval and has run three to five years behind it historically.

Assessment

DT120 pairs a rare single-dose durability signal with a molecule that costs nothing to make. The clinical case is already strong. The valuation case is unusual, because the moat lives in the formulation and the clinical package rather than the compound, and because the bull rNPV clears the market only when the pivotals read clean. The gating variable is not whether the drug works. It is whether the FDA accepts that the blind held. The three 2026 readouts, and the blinding statistics inside them, decide both the approval and whether the $4.4B is early or late.

Key sources